Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Impact of maintenance strategies post-autologous stem cell transplant in patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities

Arvind Suresh, Kwan-Keat Ang, Jodi Lipof et al. Nov 03, 2025 pp. 2805-2805 10.1182/blood-2025-2805

Abstract Introduction Outcomes for patients with newly diagnosed multiple myeloma (NDMM) who have high-risk cytogenetic...

Feasibility and utility of unmatched whole-genome sequencing (uWGS)  for pediatric acute leukemias: An analysis of leukemia precision-based therapy (LEAP) study samples

Jesús Gutiérrez-Abril, Dylan Domenico, Gunes Gundem et al. Nov 03, 2025 pp. 2561-2561 10.1182/blood-2025-2561

Abstract Introduction For children with acute leukemias, rapid and accurate assessment of genomic biomarkers is essential for optimal diagno...

Targeting the casein kinase II /ikaros axis sensitizes TKI activity by suppression of GLUT1 expression and glycolysis in ph+ ALL

Linyao Zhang, Qi Han, Huimin Xiang et al. Nov 03, 2025 pp. 3305-3305 10.1182/blood-2025-3305

Abstract Background The survival rate of Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was significantly incre...

The molecular landscape of patients with malignant histiocytosis

Alanis Rodriguez-Rosario, Jithma Abeykoon, N. Nora Bennani et al. Nov 03, 2025 pp. 7335-7335 10.1182/blood-2025-7335

Abstract Purpose. Malignant histiocytoses (MHs) including Langerhans cell sarcoma (LCS), interdigitating dendritic cell sarcoma (IDCS), and...

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Atharva Karulkar, Hasmukh Jain, Devanshi Kalra et al. Nov 03, 2025 pp. 1076-1076 10.1182/blood-2025-1076

Abstract Background: In India, access to curative therapies for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) remains...

Inflammatory signaling selectively disrupts GATA factor-regulated networks governing erythroid differentiation and hemoglobin synthesis

Ruiqi Liao, Zhongxuan Sun, Siqi Shen et al. Nov 03, 2025 pp. 1120-1120 10.1182/blood-2025-1120

Abstract Chronic inflammation, often associated with aging, instigates anemia of inflammation (AI) that afflicts hundreds of thousands in th...

Targets of BTK and IRAK4 pathways in cns lymphoma: Identification of CXCL10 as a prognostic biomarker in CSF and its receptor, CXCR3, as a mediator of pro-survival signaling

Ming Lu, Huimin Geng, Lingjing Chen et al. Nov 03, 2025 pp. 5321-5321 10.1182/blood-2025-5321

Abstract The pathogenesis of primary CNS lymphoma (PCNSL) is dependent upon constitutive activation of nuclear factor-kappa B (NF-kB) signal...

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Anath Lionel, Lorenzo Gensini, Sherif Seif et al. Nov 03, 2025 pp. 1829-1829 10.1182/blood-2025-1829

Abstract Introduction:Waldenström macroglobulinemia (WM), the most common subtype of lymphoplasmacytic lymphoma (LPL), is characterized by t...

Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples

Minakshi Guha, Kai Ding Nov 03, 2025 pp. 7044-7044 10.1182/blood-2025-7044

Abstract Background: Measurable residual disease (MRD) detection is a critical prognostic tool in acute myeloid leukemia (AML), guiding trea...

Breaking geographic barriers in a Mexican ambulatory transplant program: Early outcomes in a diverse national and international cohort

Yadith Karina Lopez-Garcia, Alejandra De Las Fuentes, Perla R. Colunga-Pedraza et al. Nov 03, 2025 pp. 722-722 10.1182/blood-2025-722

Abstract Background: Access to hematopoietic cell transplantation (HCT) in Latin America remains highly centralized. The lack of regional tr...

A combinatorial caar-T cell strategy to eliminate factor VIII inhibitors in preclinical models of Hemophilia A

Wenjie Li, Xin He, Yan Chen Nov 03, 2025 pp. 304-304 10.1182/blood-2025-304

Abstract Background Chimeric Autoantibody Receptor T (CAAR-T) cell therapy, an extension of chimeric antigen receptor T cell (CAR-T) technol...

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Joanna Rhodes, Adam Kittai, Paul Hampel et al. Nov 03, 2025 pp. 2720-2720 10.1182/blood-2025-2720

Abstract Background The treatment (tx) landscape for chronic lymphocytic leukemia (CLL) has evolved, with National Comprehensive Cancer Netw...

Neonatal fc receptor antagonists in adult patients with primary immune thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials

Sinrraim dos Santos Chaves Ruiz, Daniela Castro Calderón, Carolina Alves Felippe et al. Nov 03, 2025 pp. 4816-4816 10.1182/blood-2025-4816

Abstract Introduction Primary immune thrombocytopenia (ITP) is an autoimmune condition marked by low platelet counts due to antibody-mediate...

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Max Steinhardt, Eli Muchtar, Taxiarchis Kourelis et al. Nov 03, 2025 pp. 3962-3962 10.1182/blood-2025-3962

Abstract Background: Gastrointestinal (GI) symptoms are frequent in patients (pts) with systemic light chain amyloidosis (AL), yet their clin...

Novel prognostic scoring system for hematopoietic stem cell transplantation in myelodysplastic syndrome and Acute Myeloid Leukemia, myelodysplasia-related

Shunsuke Nishino, Hisashi Yamamoto, Go Yamamoto et al. Nov 03, 2025 pp. 7829-7829 10.1182/blood-2025-7829

Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for adva...

Outcomes of long-term anticoagulation use in patients hospitalized with sickle cell vaso-occlusive crisis: A weighted analysis of the national inpatient sample (2016–2022)

Abdulmalek Aljafari, Abdel Rahem Yusuf, Abdulmoiz Aljafari et al. Nov 03, 2025 pp. 6500-6500 10.1182/blood-2025-6500

Abstract Background: Sickle cell disease is associated with both thrombotic and hemorrhagic complications, particularly during vaso-occlusiv...

Chick embryo xenograft model of multiple myeloma recapitulates immune response, systemic dissemination, and sensitivity to anti-myeloma therapeutics

Izabela Cymer, Cerelia Yoong, Catherine Richards et al. Nov 03, 2025 pp. 5082-5082 10.1182/blood-2025-5082

Abstract Introduction Multiple myeloma (MM) is an incurable plasma cell cancer comprising ~2% of cancer diagnoses and 10% of hematologic mal...

Arvenacogene sanparvovec: A novel gene therapy for hemophilia B – results from A phase I–II first-in-human trial

Vadim Ptushkin, Nadezhda Zozulya, Igor Davydkin et al. Nov 03, 2025 pp. 4313-4313 10.1182/blood-2025-4313

Abstract Introduction: ANB-002 (INN: arvenacogene sanparvovec) is a gene construct for the therapy of hemophilia B. It utilizes an adeno-ass...

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Abena Prempeh, Myra Robinson, Zalak Shah et al. Nov 03, 2025 pp. 6347-6347 10.1182/blood-2025-6347

Abstract Background: T-cell redirecting therapies (TCRT), including CAR T-cell and bispecific antibodies have emerged as a new pillar of tre...

Global, regional, and national burden of myelodysplastic, myeloproliferative, and other hematopoietic neoplasms from 1990 to 2021, and projections to 2050: A systematic analysis for the global burden of disease study 2021

Jieya Luo, Jiwei Lin, Mingyang Wang et al. Nov 03, 2025 pp. 4610-4610 10.1182/blood-2025-4610

Abstract Background: Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and related hematopoietic neoplasms (collectively...

Initial experience with anti-CD19 CAR-T cell therapy in patients with Relapsed/Refractory diffuse large B-cell lymphoma in a brazilian cancer center

Bianca Cal, Breno Aires de Souza, Julia Ferreira Campos et al. Nov 03, 2025 pp. 7237-7237 10.1182/blood-2025-7237

Abstract INTRODUCTION: Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 has emerged as a promising therapeutic modality for p...

Determining barriers to access first-line treatment in high volume facilities in adolescents and young adults (AYA) with acute leukemias

Laneisha Maldonado Jaime, Tarrant McPherson, Yuan Liu et al. Nov 03, 2025 pp. 4625-4625 10.1182/blood-2025-4625

Abstract Adolescents and young adults (AYA) with acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (A...

Non-invasive detection and classification of lymphoma via cell-free DNA methylation profiling

Victoria Shelton, Mohamed Alias, Ting Liu et al. Nov 03, 2025 pp. 1748-1748 10.1182/blood-2025-1748

Abstract Diagnosing lymphoma relies on invasive tissue biopsies, which can yield insufficient material for histopathological evaluation and...

Bispecific antibody therapy in multiple myeloma is impaired by tumor-associated macrophages through dual immunosuppressive and antigen-dependent mechanisms

Vivien Reinecke, Kereshmeh Tasbihi, Maike Büttner-Herold et al. Nov 03, 2025 pp. 5711-5711 10.1182/blood-2025-5711

Abstract Multiple myeloma (MM) is a malignant plasma cell disorder primarily affecting the bone marrow. Advances such as proteasome inhibito...

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag et al. Nov 03, 2025 pp. 2226-2226 10.1182/blood-2025-2226

Abstract Background: Bispecific antibodies (bsAb) have revolutionized the care of patients with multiple myeloma (MM); however, they are als...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page